

INDEX

Note: Entries followed by “f” denote figures; “t” tables.

- AAP (American Academy of Pediatrics) guidelines, 130
Abelcet, 146t-147t. *See also* AmB (amphotericin B).
Abscess, 151-152
 brain, 151
 orbital, 151
 superiosteal osteal, 151
Acanthamoeba spp, 96t, 148
Acinetobacter spp, 125
Acnes, *Propionibacterium*, 108t
Acquired immune deficiency syndrome. *See* AIDS (acquired immune deficiency syndrome).
Acute bacterial sinusitis, 9, 101-112
 vs acute otitis media, 101
 antimicrobial resistance and, 101-104, 102t, 103f, 105t
 β-lactamase production, 104-108, 106f, 107t-108t
 cross-resistance, 109t
 risk factors for, 110, 110t
 shielding phenomenon, 106f
 fundamentals of, 9, 101
 recommendations for, 114, 130-131, 132f-133f, 134t-136t, 137
 therapies for, 102t
Acute exacerbation of chronic sinusitis. *See* AECS (acute exacerbation of chronic sinusitis).
Acute otitis media, 101
Adenoids, 67t, 155t
 enlarged, 155t
 hypertrophy, 28t, 67t
Adjuvant therapies, 102t, 141-144
 antihistamines, 102t, 141-143
 cetirizine, 143
 chlorpheniramine, 143
 diphenhydramine, 143
 fexofenadine, 143
 first-generation, 143
 hydroxyzine, 143
 loratadine, 143
 meclizine, 143
 promethazine, 143
 second-generation, 143
 tripeleennamine, 143
 antiinflammatory agents, 141
 corticosteroids, 102t, 141, 143-144
 budesonide, 143
 flunisolide, 143
 fluticasone, 143
 systemic, 143-144
 topical, 143
 triamcinolone acetonide, 143
 Adjuvant therapies (*continued*)
 cromolyn sodium, 144
 decongestants, 102t, 141, 143
 systemic, 102t, 141
 topical, 102t, 141, 143
 fundamentals of, 141
 hot dry air as, 141-142
 humidification, 142
 mucolytic agents, 102t, 142
 mucoregulatory agents, 142
 nasal lavage, 141-142
 nasal saline irrigation/spray, 141-142
 reference resources for, 144
 spicy food as, 141
 Adult vs pediatric dosages, 116t-119t
 AECS (acute exacerbation of chronic sinusitis), 12t, 13f, 93
 Aerobes vs anaerobes, 80f-81f, 83-85, 84t, 86t, 88t-89t, 92t, 114-115, 118t-119t, 145-148
 Agents, antimicrobial. *See* Antimicrobial agents.
 AIDS (acquired immune deficiency syndrome), 66t-67t
 Alcohol consumption, concomitant, 124
 Allergies, 14t, 15f, 35, 47, 130-134, 132f-133f, 135t
 allergic sinusitis, 47
 laboratory tests for, 35
 penicillin, 130-134, 132f-133f, 135t
 vs sinus infections, 14t, 15f
 Alternaria spp, 95, 145, 146t-147t
 Amantadine, 155t
 AmB (amphotericin B), 146t-147t
 AmBisome, 146t-147t. *See also* AmB (amphotericin B).
 American Academy of Pediatrics. *See* AAP (American Academy of Pediatrics) guidelines.
 Aminoglycosides, 113-115, 148
 Amoxicillin, 114-120, 116t-119t, 130-131, 132f-133f, 134t, 135t-136t
 Amoxicillin plus clavulanate, 82, 114, 116t-119t, 120-121, 130-131, 132f-133f, 135t-136t, 138, 138t
 Amoxil, 116t-117t. *See also* Amoxicillin.
 Amphotericin B. *See* AmB (amphotericin B).
 Anaerobes vs aerobes, 80f-81f, 83-85, 84t, 86t, 88t-89t, 92t, 114-115, 118t-119t, 145-148
 Anaphylaxis, 132f-133f
 Anatomical blockages, 67t, 130t
 Anatomy, 51-60
 developmental considerations, 51, 52f-53f, 54t
 ethmoid sinus, 51, 52f-53f, 56
 frontal sinus, 51, 52f-53f, 56
 fundamentals of, 51, 52f-53f
 maxillary sinus, 51, 52f-53f, 55-56, 55f
 meati, 57-58
 nasal turbinates, 51, 52f-53f, 57
 OMC, 52f, 57-59, 59f
 reference resources for, 60
 sphenoid sinus, 56-57

Antibacterial agents. *See* Antimicrobial agents.

Anticoagulants, oral, 124

Antifungal agents, 145-148, 146t-147t

AmB, 145, 146t-147t

immunocompromised hosts and, 145-148. *See also*

Immunocompromised hosts.

itraconazole, 145, 146t-147t

voriconazole, 145, 146t-147t

Antihistamines, 102t, 142-143

cetirizine, 143

chlorpheniramine, 143

diphenhydramine, 143

fexofenadine, 143

first-generation, 143

hydroxyzine, 143

loratadine, 143

meclizine, 143

promethazine, 143

second-generation, 143

tripelennamine, 143

Antihypertensives, 67t

Antiinflammatory agents, 141

Antimicrobial agents, 113-140. *See also under individual drug names and classes.*

β -lactamase inhibitors, 114-115, 116t-117t, 124, 134-135, 148

adult vs pediatric dosages, 116t-119t

aminoglycosides, 113-115, 148

carbapenems, 101, 118t-119t, 125, 134-135, 148

1- β -methyl carbapenem, 125

ertapenem, 125

imipenem/cilastatin, 125, 134-135

meropenem, 125, 134-135

parenteral, 125

cephalosporins, 82, 109t, 114-115, 116t-119t, 121, 130-131, 132f-133f,

135t-136t, 138, 138t, 148

cefaclor, 118t-119t, 121

cefdimir, 82, 108, 116t-118t, 120-121, 130-131, 132f-133f, 136t, 138, 138t

cefepime, 115

cefixime, 109t, 118t-119t, 121, 138, 138t

cefotaxime, 121, 132f-133f

cefopodoxime proxetil, 116t-119t, 121, 131, 132f-133f, 136t, 138, 138t

cefpodoxim, 116t-119t, 131

cefprozil, 116t-119t, 131

ceftazidime, 115, 148

ceftibuten, 109t, 118t-119t, 121

ceftriaxone, 109t, 118t-119t, 121, 131, 132f-133f, 136t

cefuroxime axetil, 116t-119t, 121, 131, 132f-133f, 136t, 138, 138t

cephalexin, 118t-119t

ES, 118t-119t, 121, 131, 132f-133f, 135t

first-generation, 118t-119t, 121

fourth-generation, 115

loracarbef, 118t-119t, 121, 138, 138t

oral, 114, 121

Antimicrobial agents, cephalosporins (*continued*)

parenteral, 114, 121

second-generation, 118t-119t, 121, 131, 135t

third-generation, 118t-119t, 121, 131, 135t

clinical trials and research studies of, 114-125

cost-related factors for, 115, 137-138

drug interactions with, 124-127

efficacy of, 114-125

epidemiology, 9

fundamentals of, 113

for fungal bacterial sinusitis, 115

glycopeptides (vancomycin), 115, 123

hypersensitivity reactions to, 122

ketolides (telithromycin), 114, 122-123

lincosamides (clindamycin), 109t, 116t-119t, 122

macrolides, 83, 114, 116t-119t, 122, 131, 132f-133f, 134-135, 138, 138t

azalides (azithromycin), 116t-119t, 122, 138, 138t

clarithromycin, 116t-119t, 122, 138, 138t

erythromycin, 118t-119t, 122

erythromycin plus sulfisoxazole acetyl, 122

metronidazole, 114-115, 123-124, 134-135

metronidazole plus penicillin, 134-135

oral, 116t-117t

oxazolidinones (linezolid), 123

penicillins, 82, 114-121, 116t-119t, 130-135, 132f-133f, 135t

amoxicillin, 114-120, 116t-119t, 130-131, 132f-133f, 134t, 135t-136t

amoxicillin plus clavulanate, 82, 114, 116t-119t, 120-121, 130-131,

132f-133f, 135t-136t, 138, 138t

metronidazole plus penicillin, 134-135

penicillin allergies, 130-131, 132f-133f, 134-135, 135t

piperacillin, 114

ticarcillin, 114

ticarcillin plus clavulanate, 134

prevention strategies and, 155, 155t

quinolones, 113-115, 124, 131, 136t, 138, 138t, 148

ciprofloxacin, 115, 124, 138, 138t

fluoroquinolones, 124

gatifloxacin, 109t, 114, 124, 131, 136t

gemifloxacin, 124, 131, 136t

levofloxacin, 109t, 114, 124, 131, 136t

moxifloxacin, 114, 124, 131, 136t

ofloxacin, 124

phototoxic potential and, 124

pneumococcal, 124

respiratory, 114, 124, 131

trovafloxacin, 124

recommendations for, 129-140

AAP guidelines, 130

acute bacterial sinusitis, 114, 130-131, 132f-133f, 134t-136t, 137

acute bacterial sinusitis, uncomplicated, 132f-133f

bacteriologic eradication, 129-130

chronic bacterial sinusitis, 114-115, 134-135, 137

Antimicrobial agents, recommendations (*continued*)

compliance factors, 137-138
duration criteria, 116t-117t, 137
empirical parameters, 129-130
maxillary sinusitis of dental origin (acute vs chronic), 131-134
oral suspension taste factors, 137-138, 138t
selection criteria, 113
therapy goals, 129-130
treatment failure and, 129-130, 130t
reference resources for, 126-127, 138
resistance factors, 83, 103f, 113, 115-116, 120-121
rifampin, 109t
shielding phenomenon and, 106f, 113
surgical drainage and, 115
tazobactam, 114
telithromycin, 109t
tetracycline, 109t
TMP-SMX, 109t, 114-115, 116t-119t, 122, 131, 135, 138, 138t
toxicity of, 137
trimethoprim, 114-115, 116t-119t, 122, 138, 138t
in vitro efficacy of, 118t-119t, 122
Aspergillus spp, 86t, 94-95, 96t, 146t-147t, 148
Aspergillus flavus, 94
Aspergillus fumigatus, 94
Aspergillus niger, 94
Aspiration, sinus, 32-33, 32t, 34f
Aspirin, 66t-67t
Assessments, required, 28t
Asthma, 11, 14t-15t, 73-74, 155t
Ataxia-telangiectasia, 66t-67t
Augmentin, 116t-117t. *See also* Amoxicillin plus clavulanate.
Azalides (azithromycin), 116t-119t, 122, 138, 138t

Bacterial interference, 82
Bacteriologic eradication, 129-130
Bacteriostatic agents. *See* Antimicrobial agents.
Bacteroides fragilis, 108t, 114-115
Bactrim, 116t-117t. *See also* TMP-SMX (trimethoprim-sulfamethoxazole).
β-Lactamase, 83, 87, 91f, 92, 104-108, 105t, 106f, 107t-108t, 114-115, 116t-117t, 120-124, 135-134, 148
β-lactamase producing bacteria. *See* BLPB (β-lactamase producing bacteria).
inhibitors, 114-115, 116t-117t, 124, 134-135, 148
production, 83, 87, 91f, 92, 104-108, 105t, 106f, 107t-108t, 114-115, 120-121
shielding, 106f, 113
Biaxin, 116t-117t. *See also* Clarithromycin.
Biopsy, 146t-147t
Bipolaris spp, 94, 146t-147t
Birth control pills, 67t
Blastomyces dermatitidis, 94
Blood dyscrasias, 66t-67t

BLPB (β-lactamase producing bacteria), 83, 87, 91f, 92, 104-105, 105t, 106f, 107t-108t, 114-115, 120-121
Brain abscess, 151
Bronchodilators, 73-74
Budesonide, 143

Candida spp, 94, 96t
Capnocytophaga spp, 123-124
Carbapenems, 101, 118t-119t, 125, 134-135, 148
1-β-methyl carbapenem, 125
ertapenem, 125
imipenem/cilastatin, 125, 134-135
meropenem, 125, 134-135
parenteral, 125
Cardiac pathology, chronic, 131
Causes, infectious. *See* Infectious causes.
Cavernous sinus thrombosis, 151
CBCs (complete blood counts), 34
Cefaclor, 118t-119t, 121
Cefdinir, 82, 108, 116t-118t, 120-121, 130-131, 132f-133f, 136t, 138, 138t
Cefepime, 115
Cefixime, 109t, 118t-119t, 121, 138, 138t
Cefotaxime, 121, 132f-133f
Cefpodoxime proxetil, 116t-119t, 121, 131, 132f-133f, 136t, 138, 138t
Cefprozil, 116t-119t, 131
Ceftazidime, 115, 148
Ceftibuten, 109t, 118t-119t, 121
Ceftin, 116t-117t. *See also* Cefuroxime axetil.
Ceftriaxone, 109t, 118t-119t, 121, 131, 132f-133f, 136t
Cefuroxime axetil, 116t-119t, 121, 131, 132f-133f, 136t, 138, 138t
Cefzil, 116t-117t. *See also* Cefprozil.
Cellulitis, 38f, 151
orbital, 38f, 151
preseptal, 151
Cephalexin, 118t-119t
Cephalosporins, 82, 109t, 114-115, 116t-119t, 121, 130-131, 132f-133f, 135t-136t, 138, 138t, 148
ceftazidime, 115, 148
cefepime, 115
ceftriaxone, 109t, 118t-119t, 121, 131, 132f-133f, 136t
cefuroxime axetil, 116t-119t, 121, 131, 132f-133f, 136t, 138, 138t
cefprozil, 116t-119t, 131
ceftazidime, 115, 148
ceftibuten, 109t, 118t-119t, 121
ceftriaxone, 109t, 118t-119t, 121, 131, 132f-133f, 136t
cefuroxime axetil, 116t-119t, 121, 131, 132f-133f, 136t, 138, 138t
cephalexin, 118t-119t
ES, 118t-119t, 121, 131, 132f-133f, 135t
first-generation, 118t-119t, 121
fourth-generation, 115

- Cephalosporins (*continued*)
 loracarbef, 118t-119t, 121, 138, 138t
 oral, 114, 121
 parenteral, 114, 121
 third-generation, 118t-119t, 121, 131, 135t
 Cetirizine, 143
 CF (cystic fibrosis), 66t-67t, 75, 83
 Chemotherapy, 66t-67t
Chlamydia pneumoniae, 94
 Chlorpheniramine, 143
 Choanal atresia, 67t
 Chronic conditions, 12t, 85-92, 85t-86t, 88t-89t, 90f-91f, 92t, 105t, 108t, 114-115, 131-135, 137
 bacterial sinusitis, 12t, 85-92, 85t-86t, 88t-89t, 90f-91f, 92t, 105t, 108t, 114-115, 134-135, 137
 cardiac pathology, 131
 hepatic pathology, 131
 renal pathology, 131
Chrysosporium spp, 95
 Cilastatin/imipenem, 125, 134-135
 Cilia dyskinesia, 66t-67t
 Ciliary function alterations, 645t
 Ciprofloxacin, 115, 124, 138, 138t
Citrobacter spp, 125
 Clarithromycin, 116t-119t, 122, 138, 138t
 Clavulanic acid. *See* Amoxicillin plus clavulanate.
 Clearance tests, 31-32
 Cleocin, 116t-117t. *See also* Clindamycin.
 Clindamycin, 109t, 116t-119t, 122
 Clinical diagnoses, 11, 12t, 13f, 14t-17t, 18f-19f. *See also* Diagnoses.
 Clinical trials and research studies, 114-125
Clostridium perfringens, 125
 Cocaine, 67t
 Comorbidity factors, 131, 155t
 Complement deficiency, 66t-67t
 Complete blood counts. *See* CBCs (complete blood counts).
 Compliance factors, 137-138
 Complicated ethmoidal sinusitis, 135t
 Complications, 151-152
 fundamentals of, 151
 intracranial, 151
 orbital, 151
 reference resources for, 152
 Computed tomography. *See* CT (computed tomography).
 Concha bullosa, 67t
 Concomitant alcohol consumption, 124
 Congenial immunodeficiency, 155t
 Congenital abnormalities, 155t
 Contraceptives, oral, 67t
 Cortical vein thrombosis, 151
 Corticosteroids, 102t, 141, 143-144
 budesonide, 143
 flunisolide, 143
 fluticasone, 143
 systemic, 143-144
 topical, 143
 triamcinolone acetonide, 143
 Cost-related factors, 9
 Cromolyn sodium, 144
 Cross-resistance, 109t
Cryptococcus spp and *Cryptococcus neoformans*, 94, 96t, 148
Cryptosporidium spp, 96t, 148
 CT (computed tomography), 40-45, 41f-45f. *See also* Imaging techniques.
 Cudwell views, 39-40, 39f
Curvularia spp and *Curvularia lunata*, 95, 146t-147t
 Cystic fibrosis. *See* CF (cystic fibrosis).
 Cytomegalovirus, 96, 148
 Daycare attendance, 110, 110t
 Debridement, surgical, 145
 Decongestants, 67t, 102t, 141, 143
 systemic, 102t, 141
 topical, 102t, 141, 143
 Definition criteria, 12t, 13f
 Dental infections, 75. *See also* Odontogenic pathological conditions.
 Dental pain, 17t
 Developmental considerations, 51, 52f-53f, 54t
 Deviated septum, 67t
 Diabetes, 66t-67t, 75, 94, 131, 145-148, 155t
 Diagnoses, 11-30
 allergy vs sinus infection, 14t, 15f
 clinical, 11, 12t, 13f, 14t-17t, 18f-19f
 definition criteria, 12t, 13f
 diagnostic/laboratory tests and. *See* Diagnostic/laboratory tests.
 fundamentals of, 11, 12t, 13f
 major vs minor criteria, 17t
 medical histories, 14t, 16t
 physical examination findings, 14t, 16t, 20-23, 21t, 22f, 24t-26t
 practical criteria for, 11, 17t, 18f-19f
 reference resources for, 29
 required assessments, 28t
 symptoms, 14t
 Diagnostic/laboratory tests, 31-36
 diagnostic tests, 31-34
 mucociliary clearance, 31-32
 rhinomanometry, 33-34
 sinus aspiration, 32-33, 32t, 34f
 translumination, 31
 fundamentals of, 31
 imaging techniques, 37-50. *See also* Imaging techniques.
 laboratory tests, 34-35
 allergy, 35
 CBCs, 34

Diagnostic/laboratory tests, laboratory tests (*continued*)

ESRs, 34
HIV, 35
serum immunoglobulin, 34
of sinus aspiration, 33
sweat chloride evaluations, 35
reference resources for, 35
Diphenhydramine, 143
Disulfiram-like reactions, 124
Dosages, adult vs pediatric, 116t-119t
Drug interactions, 124-127
Duration criteria, 116t-117t, 137
Dyscrasias, blood, 66t-67t
Dyskinesia, cilia, 66t-67t

Edema, inflammatory, 24t-25t, 151
Efficacy, antimicrobial agents, 114-125. *See also* Antimicrobial agents.
Elevated protein concentration levels, 113
Emericella nidulans, 94
Empirical parameters, 129-130
Empyema, epidural vs subdural, 151
Endoscopy, 28t
Enlarged adenoids, 155t
Enlarged tonsils, 155t
Enterobacteriaceae, 85t-86t, 145
Enterococcus spp, 123, 125
 Enterococcus faecalis, 123
 Enterococcus faecium, 123, 125
Epidemiology, 9-10
Epidural empyema, 151
Eradication, bacteriologic, 129-130
Erm(B), 123
Ertapenem, 125
Erythema, 24t-25t
Erythrocyte sedimentation rates. *See* ESRs (erythrocyte sedimentation rates).
Erythromycin, 118t-119t, 122
Erythromycin plus sulfisoxazole acetyl, 122
ES (extended-spectrum) cephalosporins, 118t-119t, 121, 131, 132f-133f, 135t
ESRs (erythrocyte sedimentation rates), 34
Ethmoid sinus, anatomy of, 51, 52f-53f, 56
Ethmoidal sinusitis, 24t-25t, 24t-27t, 135t
Examination findings, 14t, 16t, 20-23, 21t, 22f, 24t-26t
Exserohilum spp, 95
Extended-spectrum cephalosporins. *See* ES (extended-spectrum) cephalosporins.

Facial osteomyelitis, 151
Facial trauma, 67t
Fexofenadine, 143
Film radiography. *See* PFR (plain film radiography).
Findings, 14t, 16t, 20-23, 21t, 22f, 24t-26t
First-generation antihistamines, 143

First-generation cephalosporins, 118t-119t, 121. *See also* Cephalosporins.
Fluoroquinolones, 124. *See also* Quinolones.
Fluticasone, 143
Foreign bodies, 67t, 155t
Fourth-generation cephalosporins, 115
Frontal sinus, anatomy of, 51, 52f-53f, 56
Frontal sinusitis, 24t-25t, 24t-27t, 135t, 153t
Fundamental concepts. *See also under individual topics.*
 for acute bacterial sinusitis, 9, 101
 for adjuvant therapies, 141
 for anatomy, 51, 52f-53f
 for antimicrobial agents, 113
 for complications, 151
 for diagnoses, 11, 12t, 13f
 for imaging techniques, 37
 for immunocompromised hosts, 145
 for infectious causes, 79
 for laboratory/diagnostic tests, 31
 for pathophysiology, 61
 for predisposing factors, 73, 130t
Fungal bacterial sinusitis, 47, 94-96, 115
Fungi and molds, 86t, 94, 146t-147t, 148. *See also* Pathogens and causative agents.
Fusarium, 146t-147t
Fusobacterium spp and *Fusobacterium nucleatum*, 81f, 85-87, 86t, 90f-91f, 105t, 108t, 114-115, 125

GABHS (group A β -hemolytic streptococci), 122
Gastroesophageal reflux, 66t-67t
Gatifloxacin, 109t, 114, 124, 131, 136t
Gemifloxacin, 124, 131, 136t
Genetic predisposing factors, 74
Glycopeptides (vancomycin), 115, 123
Gram-positive vs Gram-negative pathogens, 94, 103f, 123, 145-148
Granulomatous disease, 66t-67t
Group A β -hemolytic streptococci. *See* GABHS (group A β -hemolytic streptococci).

Haemophilus influenzae, 81f, 82-87, 84t-86t, 91f, 93, 105t, 114-116, 118t-119t, 120-125
Halitosis, 17t
Haller air cells, 67t
Hepatic pathology, chronic, 131
Histories, 14t, 16t
HIV, 74-75, 83
HIV (human immunodeficiency virus) infections, 35, 74-75, 83, 145-148
Hosts, immunocompromised. *See* Immunocompromised hosts.
Hot dry air as adjuvant therapy, 141-142
Human immunodeficiency virus infections. *See* HIV (human immunodeficiency virus) infections.
Humidification, 142
Hyaline molds, 145, 146t-147t

- Hydantoins, 124
 Hydroxyzine, 143
 Hyper IgM syndrome, 66t-67t
 Hyperemia, 24t-25t
 Hypermetabolism, 66t-67t
 Hypersensitivity reactions, 122
 Hyposmia, 16t
 Hypothyroidism, 155t
- Imaging techniques, 37-50. *See also* Diagnostic/laboratory tests.
 for allergic sinusitis, 47
 CT, 40-45, 41f-45f
 fundamentals of, 37
 for fungal bacterial sinusitis, 47
 MRI, 45-46, 46f
 objectives of, 37
 PFR, 39-41, 39f
 reference resources for, 48-49
 ultrasonography, 37-38, 38f
- Imipenem/cilastatin, 125, 134-135
 Immotile cilia syndrome, 75
- Immunocompromised hosts, 135t, 145-150
 antifungal agents and, 145-148, 146t-147t. *See also* Antifungal agents.
 causative pathogens and organisms, 145-148. *See also* Pathogens and causative agents.
 diabetes and, 145-148
 fundamentals of, 145
 HIV infections and, 145-148
 infectious causes and, 95-96, 96t. *See also* Infectious causes.
 otolaryngologist referrals for, 153t
 prevention strategies and, 155, 155t
 reference resources for, 149
- Immunoglobulin, 34, 71-75, 85
 IgA, 71, 74-75
 IgG, 85
 IgG₂, 74-75
 IgG₃, 74-75
 serum immunoglobulin tests, 34
- In vitro* efficacy, antimicrobial agents, 118t-119t, 122
- Infectious causes, 79-100. *See also* Pathogens and causative agents.
 bacteria, 82-94
 in acute sinusitis, 82-86, 84t-86t
 in AECs, 93
 in chronic bacterial sinusitis, 85-92, 85t-86t, 88t-89t, 90f-91f, 92t
 in sinusitis of dental origin (acute vs chronic), 93-94
 dynamics of, 80f-81f
 fundamentals of, 79
 fungal infections, 94-95
 immunocompromised hosts and, 95-96, 96t. *See also* Immunocompromised hosts.
 interfering flora, 82
 reference resources for, 96-99
- Infectious causes (*continued*)
 viral infections, 79-81, 80f-81f
 influenza viruses, 79
 mechanisms of, 79
 parainfluenza viruses, 79
 rhinoviruses, 79
 viral URTIs, 79-81, 80f-81f
 virus-pathogenic bacteria synergy, 79
- Inflammatory conditions, 66t-67t, 151
 Influenza viruses, 79
 Interference, bacterial, 82
 Interfering flora, 82
 Intracranial complications, 151
 Intubation, 67t, 145
 Irrigation, saline, 141-142
 Irritants, 71-72, 72f
 Itraconazole, 145, 146t-147t
- Kartagener's syndrome, 66t-67t, 75
 Ketolides (telithromycin), 114, 122-123
Klebsiella spp and *Klebsiella pneumoniae*, 125, 145
- Laboratory/diagnostic tests, 31-36
 diagnostic tests, 31-34
 mucociliary clearance, 31-32
 rhinomanometry, 33-34
 sinus aspiration, 32-33, 32t, 34f
 translumination, 31
 fundamentals of, 31
 imaging techniques, 37-50. *See also* Imaging techniques.
 laboratory tests, 34-35
 allergy, 35
 CBCs, 34
 ESRs, 34
 HIV, 35
 serum immunoglobulin, 34
 of sinus aspiration, 33
 sweat chloride evaluations, 35
 reference resources for, 35
- Lateral views, 39-40, 39f
 Lavage, nasal, 141-142
Legionella spp, 96
 Levofloxacin, 109t, 114, 124, 131, 136t
 Lincosamides (clindamycin), 109t, 116t-119t, 122
 Linezolid, 123
Listeria monocytogenes, 96
 Loracarbef, 118t-119t, 121, 138, 138t
 Loratadine, 143
- Macrolides, 83, 114, 116t-119t, 122, 131, 132f-133f, 134-135, 138, 138t
 azalides (azithromycin), 116t-119t, 122, 138, 138t
 clarithromycin, 116t-119t, 122, 138, 138t

- Macrolides (*continued*)
 erythromycin, 118t-119t, 122
 erythromycin plus sulfisoxazole acetyl, 122
- Magnetic resonance imaging. *See* MRI (magnetic resonance imaging).
- Malnutrition, 66t-67t
- Management and diagnosis (pediatric sinusitis) concepts. *See also under individual topics.*
 acute bacterial sinusitis, 101-112
 adjuvant therapies, 141-144
 anatomy, 51-60
 antimicrobial agents, 113-140
 complications, 151-152
 diagnoses, 11-30
 epidemiology, 9-10
 fundamentals. *See* Fundamental concepts.
 imaging techniques, 37-50
 immunocompromised hosts, 145-150
 infectious causes, 79-100
 laboratory/diagnostic tests, 31-36
 otolaryngologist referrals, 153-154
 pathophysiology, 61-72
 predisposing factors, 73-78
 prevention, 155
 reference resources for. *See* Reference resources.
- Marijuana smoking, 94
- Maxillary sinus, anatomy of, 51, 52f-53f, 55-56, 55f
- Maxillary sinusitis, 24t-27t, 91f
- Meati, anatomy of, 57-58
- Mechanical blockages, 67t
- Meclizine, 143
- Medical histories, 14t, 16t
- Mef(A)*, 123
- Meningitis, 151
- Meropenem, 125, 134-135
- Methicillin-resistant *Staphylococcus aureus*. *See* MRSA (methicillin-resistant *Staphylococcus aureus*).
- Metronidazole, 114-115, 123-124, 134-135
- Metronidazole plus penicillin, 134-135
- Molds and fungi, 86t, 94, 146t-147t, 148. *See also* Pathogens and causative agents.
- Monosporium apiospermum*, 94
- Moraxella catarrhalis*, 81f, 82-87, 84t-86t, 91f, 93, 105, 115-116, 118t-119t, 121-125
- Moxifloxacin, 114, 124, 131, 136t
- MRI (magnetic resonance imaging), 45-46, 46f. *See also* Imaging techniques.
- MRSA (methicillin-resistant *Staphylococcus aureus*), 87, 115, 123-125
- Mucocele, 151
- Mucociliary apparatus, 61-65, 62f
 mucous blanket, 61-63, 62f
 ostia, 61-63, 62f, 69f
- Mucociliary clearance tests, 31-32
- Mucociliary dysfunction, 75
- Mucolytic agents, 102t, 142
- Mucor* spp, 94, 96t, 145, 146t-147t
- Mucoregulatory agents, 142
- Mucous blanket, 61-63, 62f
- Multiple-organ dysfunction, 66t-67t
- Mycobacterium* spp and *Mycobacterium kansasii*, 148
- Mycoplasma pneumoniae*, 94
- Nasal lavage, 141-142
- Nasal polyps, 28t, 67t, 153t, 155t
- Nasal saline irrigation/spray, 141-142
- Nasal turbinates, 51, 52f-53f, 57
- Nasogastric catheters and tubes, 67t, 145
- Nasotracheal catheters and tubes, 67t, 84, 145
- Negative nutrition, 66t-67t
- Neisseria*, 125
- Neutropenic patients, 145. *See also* Immunocompromised hosts.
- Nonallergic bacterial sinusitis, 144
- Nonsevere acute sinusitis, 21t
- Nonurgent referrals, 153-154, 153t
- Nosocomial sinusitis, 145, 153t
- Obstructive polypoid disease, 75
- Odontogenic pathological conditions, 131-134
- Odontogenic sinusitis, 75
- Ofloxacin, 124
- OMC (ostiomeatal complex), 52f, 57-59, 59f, 73
- Omnicef, 116t-117t. *See also* Cefdinir.
- Oral agents, 67t, 114, 121, 124, 137-138, 138t. *See also* Antimicrobial agents.
 anticoagulants, 124
 antimicrobial, 116t-117t
 cephalosporins, 114, 121
 contraceptives, 67t
 suspension taste factors, 137-138, 138t
- Orbital complications, 38f, 151
 abscess, 151
 cellulitis, 38f, 151
- Oreschlera* spp, 94
- Ostiomeatal complex. *See* OMC (ostiomeatal complex).
- Osteomyelitis, facial, 151
- Ostia, 61-63, 62f, 69f
- Ostial obstruction, 71
- Otitis media, acute, 101
- Otolaryngologist referrals, 153-154, 153t
- Oxazolidinones (linezolid), 123
- Paecilomyces* spp, 94, 146t-147t
- Parainfluenza viruses, 79
- Parasites, 148
- Parenteral antimicrobial agents, 114, 121-125. *See also* Antimicrobial agents.
 carbapenems, 125
 cephalosporins, 114, 121

Particulate matter, 72f
Pathogens and causative agents, 79-100. *See also* Infectious causes.
Acanthamoeba spp, 96t, 148
Acinetobacter spp, 125
aerobes vs anaerobes, 80f-81f, 83-85, 84t, 86t, 88t-89t, 92t, 114-115, 118t-119t, 145-148
Bacteroides fragilis, 108t, 114-115
BLPB, 83, 87, 91f, 92, 104-105, 105t, 106f, 107t-108t, 114-115, 120-121
Capnocytophaga spp, 123-124
Chlamydia pneumoniae, 94
Citrobacter spp, 125
Clostridium perfringens, 125
Cryptosporidium spp, 96t, 148
Enterobacteriaceae, 85t-86t, 145
Enterococcus spp, 123, 125
 Enterococcus faecalis, 123
 Enterococcus faecium, 123, 125
fungi and molds, 86t, 94, 146t-147t, 148
Fusobacterium spp and *Fusobacterium nucleatum*, 81f, 85-87, 86t, 90f-91f, 105t, 108t, 114-115, 125
GABHS, 122
Gram-positive vs Gram-negative, 94, 103f, 123, 145-148
Haemophilus influenzae, 81f, 82-87, 84t-86t, 91f, 93, 105t, 114-116, 118t-119t, 120-125
Klebsiella spp and *Klebsiella pneumoniae*, 125, 145
Legionella spp, 96
Listeria monocytogenes, 96
Moraxella catarrhalis, 81f, 82-87, 84t-86t, 91f, 93, 105, 115-116, 118t-119t, 121-125
MRSA, 87, 115, 123-125
Mycobacterium spp and *Mycobacterium kansasii*, 148
Mycoplasma pneumoniae, 94
Neisseria, 125
parasites, 148
pathogenic bacteria-virus synergy, 79
Peptostreptococcus spp, 81f, 85-87, 86t, 91f, 108t, 125
Porphyromonas spp, 85-87, 105t
predominant, 86t
Prevotella spp and *Prevotella intermedia*, 81f, 85-87, 86t, 90f, 105t, 108t, 114-115
Propionibacterium acnes, 108t
Proteus spp, 125
Pseudomonas spp and *Pseudomonas aeruginosa*, 86t, 96, 101, 115, 124-125, 145-148
Serratia spp and *Serratia marcescens*, 125, 145
sinus cycles and, 71-72, 72f
Staphylococcus aureus, 83-86, 84t-86t, 96, 105, 108t, 114-115, 118-123, 148
Stenotrophomonas maltophilia, 125
Streptococcus spp, 81f, 82-87, 84t-86t, 91f, 93, 105t, 106-109, 108t-109t, 115-116, 118t-119t, 120-125, 145-148

Pathogens and causative agents, *Streptococcus* spp (*continued*)
 Streptococcus pneumoniae, 81f, 82-87, 84t-86t, 91f, 93, 105t, 106-109, 108t-109t, 115-116, 118t-119t, 120-125
 Streptococcus pyogenes, 84t, 125
 Toxoplasma gondii, 96t
viruses, 9, 96, 148. *See also* Viruses and viral infections.
zygotes, 145
Pathophysiology, 61-72
 ciliary function alterations, 645t
 fundamentals of, 61
 mucociliary apparatus, 61-65, 62f
 mucous blanket, 61-63, 62f
 ostia, 61-63, 62f, 69f
 mucus alterations, 64t
 predisposing factors, 66t-67t. *See also* Predisposing factors.
 reference resources for, 65
 sinusitis dynamics, 68f
Pediatric sinusitis (diagnosis and management) concepts. *See also under individual topics.*
 acute bacterial sinusitis, 101-112
 adjuvant therapies, 141-144
 anatomy, 51-60
 antimicrobial agents, 113-140
 complications, 151-152
 diagnoses, 11-30
 epidemiology, 9-10
 fundamentals. *See* Fundamental concepts.
 imaging techniques, 37-50
 immunocompromised hosts, 145-150
 infectious causes, 79-100
 laboratory/diagnostic tests, 31-36
 otolaryngologist referrals, 153-154
 pathophysiology, 61-72
 predisposing factors, 73-78
 prevention, 155
 reference resources for. *See* Reference resources.
Pediatric vs adult dosages, 116t-119t
Penicillins, 82, 114-121, 116t-119t, 130-135, 132f-133f, 135t
 amoxicillin, 114-120, 116t-119t, 130-131, 132f-133f, 134t, 135t-136t
 amoxicillin plus clavulanate, 82, 114, 116t-119t, 120-121, 130-131, 132f-133f, 135t-136t, 138, 138t
 metronidazole plus penicillin, 134-135
 penicillin allergies, 130-131, 132f-133f, 134-135, 135t
 piperacillin, 114
 ticarcillin, 114
Penicillium melinii, 94
Peptostreptococcus spp, 81f, 85-87, 86t, 91f, 108t, 125
Perennial allergic rhinitis, 144
Persistent nasal polyps, 153t
PFR (plain film radiography), 39-41, 39f. *See also* Imaging techniques.
Phagocytosis, 113
Phenobarbital, 124

- Phototoxic potential, 124
- Physical examination findings, 14t, 16t, 20-23, 21t, 22f, 24t-26t
- Piperacillin, 114
- Plain film radiography. *See* PFR (plain film radiography).
- Pneumococcal quinolones, 124. *See also* Quinolones.
- Pollutants, 71-72, 72f
- Polypoid disease, obstructive, 75
- Polyps, nasal, 28t, 67t, 153t, 155t
- Porphyromonas* spp, 85-87, 105t
- Postviral sinus syndrome, 144
- Practical criteria, diagnoses, 11, 17t, 18f-19f. *See also* Diagnoses.
- Predisposing factors, 73-78, 130t
 - allergies, 73
 - asthma, 73-74
 - dental infections, 75
 - fundamentals of, 73, 130t
 - genetic factors, 74
 - immunodeficiency, 74-75. *See also* Immunocompromised hosts.
 - HIV, 74-75
 - immunologic abnormalities, 74
 - screening indicators and, 74
 - OMC obstruction, 73
 - pathophysiology and, 65, 66t-67t. *See also* Pathophysiology.
 - reference resources for, 76-77
- Predominant pathogens and causative agents, 86t. *See also* Pathogens and causative agents.
- Preseptal cellulitis, 151
- Prevention, 155, 155t
- Prevotella* spp and *Prevotella intermedia*, 81f, 85-87, 86t, 90f, 105t, 108t, 114-115
- Promethazine, 143
- Propionibacterium acnes*, 108t
- Protein concentration levels, elevated, 113
- Proteus* spp, 125
- Pseudallescheria* spp and *Pseudallescheria boydii*, 94, 146t-147t
- Pseudomonas* spp and *Pseudomonas aeruginosa*, 86t, 96, 101, 115, 124-125, 145-148
- Quinolones, 113-115, 124, 131, 136t, 138, 138t, 148
 - ciprofloxacin, 115, 124, 138, 138t
 - fluoroquinolones, 124
 - gatifloxacin, 109t, 114, 124, 131, 136t
 - gemifloxacin, 124, 131, 136t
 - levofloxacin, 109t, 114, 124, 131, 136t
 - moxifloxacin, 114, 124, 131, 136t
 - ofloxacin, 124
 - phototoxic potential and, 124
 - pneumococcal, 124
 - respiratory, 114, 124, 131
 - trovafloxacin, 124
- Radiography. *See* PFR (plain film radiography).
- Radiological studies. *See* Imaging techniques.
- Recurrent acute sinusitis, 12t, 13f, 110, 110t, 112t, 135t, 153t
- Reference resources. *See also under individual topics.*
 - for adjuvant therapies, 144
 - for anatomy, 60
 - for antimicrobial agents, 126-127, 138
 - for complications, 152
 - for diagnoses, 29
 - for imaging techniques, 48-49
 - for immunocompromised hosts, 149
 - for infectious causes, 96-99
 - for pathophysiology, 65
 - for predisposing factors, 76-77
- Referrals, otolaryngologist, 153-154, 153t
- Renal insufficiency, 125
- Renal pathology, chronic, 131
- Required assessments, 28t
- Research studies and clinical trials, 114-125
- Residual infections, 71
- Resistance, antimicrobial, 101-104, 102t, 103f, 105t
- Resistance factors, 83, 103f, 113, 115-116, 120-121
- Respiratory quinolones, 114, 124, 131. *See also* Quinolones.
- Rhinomanometry, 33-34
- Rhinoviruses, 9, 79
- Rhizopus*, 86t, 145, 146t-147t, 148
- Rifampin, 109t
- Rimantadine, 155t
- Risk factors, predisposing, 130t
- Sagittal sinus thrombosis, 151
- Saline irrigation/spray, 141-142
- Saprophytic fungi*, 94
- Scedosporium apiospermum*, 94
- Schizophyllum commune*, 94
- Screening indicators, 74
- Seasonal allergic rhinitis, 144
- Second-generation antihistamines, 143
- Secretion hyperviscosity, 75
- Sedimentation rates. *See* ESRs (erythrocyte sedimentation rates).
- Seizures, 125
- Septal deviation, 28t, 155t
- Septic complications, 153t
- Septra, 116t-117t. *See also* TMP-SMX (trimethoprim-sulfamethoxazole).
- Serratia* spp and *Serratia marcescens*, 125, 145
- Serum immunoglobulin tests, 34
- Severe acute sinusitis, 21t
- Shielding phenomenon, 106f, 113
- Sinus aspiration, 32-33, 32t, 34f
- Sinus cycles, 71-72, 72f
 - bacterial sinusitis-leading, 71, 72f
 - healthy, 71, 72f
 - reference resources for, 71

Sinusitis (diagnosis and management) concepts. *See also under individual topics.*

acute bacterial sinusitis, 101-112
adjuvant therapies, 141-144
anatomy, 51-60
antimicrobial agents, 113-140
complications, 151-152
diagnoses, 11-30
epidemiology, 9-10
fundamentals. *See* Fundamental concepts.
imaging techniques, 37-50
immunocompromised hosts, 145-150
infectious causes, 79-100
laboratory/diagnostic tests, 31-36
otolaryngologist referrals, 153-154
pathophysiology, 61-72
predisposing factors, 73-78
prevention, 155
reference resources for. *See* Reference resources.
Sinusitis of dental origin (acute vs chronic), 93-94
Sphenoid sinus, anatomy of, 56-57
Sphenoid sinusitis, 24t-25t, 24t-27t, 135t, 153t
Spicy food as adjuvant therapy, 141
Staphylococcus aureus, 83-86, 84t-86t, 96, 105, 108t, 114-115, 118-123, 148. *See also* MRSA (methicillin-resistant *Staphylococcus aureus*).
Stenotrophomonas maltophilia, 125
Steroids. *See* Corticosteroids.
Streptococcus spp, 81f, 82-87, 84t-86t, 85t, 91f, 93, 105t, 106-109, 108t-109t 115-116, 118t-119t, 120-125, 145, 148
Streptococcus pneumoniae, 81f, 82-87, 84t-86t, 91f, 93, 105t, 106-109, 108t-109t 115-116, 118t-119t, 120-125
Streptococcus pyogenes, 84t, 125
Studies and clinical trials, 114-125
Subacute sinusitis, 12t, 13f
Subdural empyema, 151
Submentovertex views, 39-40, 39f
Sulfamethoxazole. *See* TMP-SMX (trimethoprim-sulfamethoxazole).
Sulfisoxazole acetyl, 122
Superiosteal osteal abscess, 151
Surgical debridement, 145
Surgical drainage, 115
Sweat chloride evaluations, 35
Symptoms, 14t. *See also* Diagnoses.
Synergy, pathogenic bacteria-virus, 79
Systemic agents, 102t, 141, 143-144
corticosteroids, 143-144
decongestants, 102t, 141
Taste factors, 137-138, 138t
Telithromycin, 114, 122-123
Tetracycline, 109t

Third-generation cephalosporins, 118t-119t, 121, 131, 135t. *See also* Cephalosporins.
Thrombosis, 151
Ticarcillin, 114
TMP-SMX (trimethoprim-sulfamethoxazole), 109t, 114-115, 116t-119t, 122, 131, 135, 138, 138t. *See also* Carbapenems.
Tobacco smoke exposure, 66t-67t, 110, 110t
Tomography, computed. *See* CT (computed tomography).
Tonsils, enlarged, 155t
Topical agents, 102t, 141, 143
corticosteroids, 143
decongestants, 102t, 141, 143
Toxicity, antimicrobial agents, 137
Toxoplasma gondii, 96t
Translumination, 31
Transplant patients, 94
Trials, clinical, 114-125
Triamcinolone acetonide, 143
Trimethoprim, 114-115, 116t-119t, 122, 138, 138t
Trimethoprim-sulfamethoxazole. *See* TMP-SMX (trimethoprim-sulfamethoxazole).
Trimox, 116t-117t. *See also* Amoxicillin.
Tripeleminamine, 143
Trovafloxacin, 124
Tumors, 155t
Turbinates, nasal, 51, 52f-53f, 57
Ultrasonography, 37-38, 38f. *See also* Imaging techniques.
Uncinate process, abnormal, 67t
Uncomplicated acute bacterial sinusitis, 132f-133f
Urgent referrals, 153-154, 153t
Urticaria, 14t-15t
URTIs (upper respiratory tract infections), viral. *See* Viruses and viral infections.
Vaccination considerations, 74-75, 155t
Vagal neural reflex, 74
Vancomycin, 115, 123
Vantin, 116t-117t. *See also* Cefpodoxime proxetil.
Viruses and viral infections, 9, 11, 17t, 18f-19f, 32, 66t-67t, 79-81, 80f-81f, 96, 130t, 148, 155t
cytomegalovirus, 96, 148
rhinoviruses, 9
viral load reductions, 155t
viral sinusitis, 9
viral URTIs, 11, 17t, 18f-19f, 32, 66t-67t, 79-81, 80f-81f, 130t, 155t
virus-pathogenic bacteria synergy, 79
Voriconazole, 145, 146t-147t
Water's occipital views, 39-40, 39f
Wegener's syndrome, 66t-67t
Wymox, 116t-117t. *See also* Amoxicillin.

X-linked agammaglobulinemia, 66t-67t

Young's syndrome, 66t-67t, 75

Zithromax, 116t-117t. *See also* Azalides (azithromycin).

Zygometes, 145, 146t-147t